Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examined. Although, the majority of thyroid speci®c translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described. One such translocation, TRK-T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region). To determine if TRK-T1 expression can cause thyroid cancer in vivo, we developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid. Immunohistochemical analysis of TRK-T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium. In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma. Furthermore, all transgenic mice examined greater than 7 months of age developed thyroid hyperplasia and/or carcinoma. These data support the conclusion that TRK-T1 is oncogenic in vivo and contributes to the neoplastic transformation of the thyroid. Oncogene (2000) 19, 5729 ± 5735.
Introduction
Genetic analysis of human papillary thyroid carcinomas has revealed common chromosomal translocations involving the growth factor receptors, NTRK1 (TRK-A) and c-RET, that fuse the carboxyl terminal tyrosine kinase domain of the receptor to the amino terminal region of a ubiquitously expressed partner (Bongarzone et al., 1989) . The TRK family of oncogenes result from a genetic fusion of the 3' end of NTRK1 to the 5' end of dierent partner genes . The TRK oncogene results from a paracentric inversion of chromosome 1 that joins the 5' end of Tropomyosin (TPM3) to NTRK1 (Bongarzone et al., 1989; MartinZanca et al., 1986) . Similarly, TRK-T1 results from a paracentric inversion of chromosome 1 that joins the 5' end of TPR to the 3' end of NTRK1 (Greco et al., 1992) . Dierent rearrangements involving the same two genes, TPR and NTRK1, form the family members, TRK-T2 and TRK-T4 (Greco et al., 1992) . Lastly, TRK-T3 results from a translocation of chromosomes 1 and 3 that fuses the genes, TFG (TRK fused gene) and NTRK1 (Greco et al., 1998 . Likewise, the predominant family of PTC-speci®c fusion genes involves translocation of c-RET and form fusion proteins called RET/PTC .
RET/PTC fusion proteins are expressed in 60% of PTC (Rabes and Klugbauer, 1998) , whereas NTRK1-related translocations are found less frequently, with a reported incidence of 0 ± 12% in patients with PTC (Beimfohr et al., 1999; Bongarzone et al., 1998b; Delvincourt et al., 1996; Wajjwalku et al., 1992) . Although the etiology of fusion gene formation is not clear, their appearance in patients with prior exposure to ionizing radiation is notable. For instance, recent studies of children with radiation-induced thyroid tumors from Belarus have found RET/PTC rearrangements in 78% of the PTC (Klugbauer et al., 1995 (Klugbauer et al., , 1996 . In contrast, NTRK1 translocations were identi®ed in 7% of the 81 Belarussion papillary thyroid carcinomas which were devoid of RET rearrangements (Beimfohr et al., 1999) . Thus, though translocations of both c-RET and NTRK1 are found in radiationinduced PTC, rearrangements of c-RET predominate.
Nevertheless, these studies demonstrate an association between prior ionizing radiation exposure, the presence of translocations involving NTRK1 and c-RET and the occurrence of papillary thyroid carcinoma.
Although the NTRK1 protein is known to function as a receptor for nerve growth factor, little is known about its pathological role in the genesis of thyroid carcinoma. The NTRK1 proto-oncogene has been found rearranged in human papillary thyroid carcinoma, suggesting that NTRK1 function may be important for cancer development in a manner analogous to RET/PTC (Beimfohr et al., 1999; Bongarzone et al., 1996 Bongarzone et al., , 1989 Bongarzone et al., , 1998b Greco et al., 1992; Sozzi et al., 1992; Wajjwalku et al., 1992) . In vitro, the TRK-T1 oncogene transforms NIH3T3 cells (Greco et al., 1992) . Other NTRK1 translocations transform NIH3T3 including TRK, TRK-T2 and TRK-T3 (Greco et al., 1992 Martin-Zanca et al., 1986) . However, when TRK-T1 was transfected into the rat epithelial thyroid cell line PC C13, it was unable to promote growth in soft agar or nude mice (Portella et al., 1999) . In addition, PC C13 cells transfected with the oncogene TRK-T1 retained a dierentiated phenotype that included thyroglobulin expression and a dependency on growth factor supplementation, although iodide uptake was abrogated (Portella et al., 1999) . These studies have shown that while NTRK1 translocations are able to transform NIH3T3 cells, they are unable to change the growth or dierentiation state of normal thyroid cells in vitro.
In order to study the in vivo function of thyroid speci®c oncogenes in the transformation of thyroid follicular epithelium, transgenic mouse strains were developed (Jhiang et al., 1996; Powell et al., 1998; Santoro et al., 1996) . For example, two transgenic mouse strains engineered to express the human RET/ PTC1 fusion gene in the thyroid develop follicular hyperplasia and carcinoma (Jhiang et al., 1996; Santoro et al., 1996) . Cytological features characteristics of human PTC, such as nuclear grooves and ground-glass nuclei were present, however, lymph node metastasis and local invasion were not observed and colloid production was variable between the two strains. These ®ndings possibly re¯ect dierences in transgene expression level, construct structure, or strain variability. An independent transgenic mouse strain expressing the human RET/PTC3 oncogene, frequently develops solid-type thyroid carcinomas pathologically similar to the radiation-induced carcinomas observed in humans (Powell et al., 1998) . Although cytological features such as ground-glass nuclei and nuclear grooves were not observed in RET/PTC3 transgenic mice, other features common to the human disease including papillary structures, infrequent metastasis to regional lymph nodes and solid sheets of tumor cells were found (Powell et al., 1998) . Tumor development in RET/PTC transgenic mice provides support for the theory that thyroid-speci®c fusion proteins can initiate malignant transformation of thyroid follicular epithelium.
Although the neoplastic role of RET/PTC family members has been established in vivo, translocations involving NTRK1 have not been studied. The relatively rare occurrence of NTRK1 translocations found in PTC, the inability of TRK-T1 to fully transform PC C13 cells in vitro, and the lack of a mouse strain expressing an NTRK1 fusion protein, led us to question the ability of the NTRK1 protooncogene to initiate cancer in thyroid follicular epithelium. Accordingly, we have generated transgenic mice encoding the human TRK-T1 transgene expressed in the murine thyroid under the control of the bovine thyroglobulin promoter. The development of dierentiated carcinomas in these mice supports a direct role for TRK-T1 in the development of thyroid cancer. Furthermore, TRK-T1 transgenics will be a valuable animal model to study the function of this variant thyroid oncogene.
Results

Generation and analysis of TRK-T1 transgenic mice
Thyroid-speci®c expression of the TRK-T1 fusion gene was obtained using a minigene construct containing 2 kb of the bovine thyroglobulin promoter (72036 to +9) proximal to 0.7 kb of the human b-globin intron, the complete 1.7 kb coding sequence of the human TRK-T1 fusion gene and an SV40 polyadenylation signal sequence (Figure 1 ). High-level expression of the TRK-T1 fusion protein was observed in transfected PC C13 rat thyroid cells, con®rming the functionality of this construct (Figure 2 ). To develop a transgenic mouse line, B6C3F1 zygotes were microinjected and embryos were transferred to pseudopregnant females. Progeny were genotyped using PCR and Southern blotting techniques as previously described (Powell et al., 1998) . Three independent founder lines of TRK-T1 transgenic mice were generated: 5215, 5218 and 5221. Transgene expression and tissue speci®city was veri®ed by RNase protection analysis of total RNA isolated from mouse thyroids ( Figure 3 ). All three lines expressed the TRK-T1 oncogene at similar levels when compared to a b-Actin internal control.
Immunohistochemical analysis of thyroid-specific protein expression in TRK-T1 transgenic thyroids TRK-T1 thyroids were examined using immunohistochemical techniques with an antibody speci®c for the carboxyl terminus of NTRK1. NTRK1 speci®c staining was observed in follicular epithelial cells of transgenic, but not nontransgenic thyroids ( Figure 4 and data not shown). No quantitative dierences in TRK-T1 mRNA (Figure 3 ) or protein (data not shown) expression were observed between the transgenic lines 5215, 5218 and 5221. TRK-T1 transgenic thyroids retained a dierentiated phenotype as indicated by the staining of colloid with an antibody speci®c for thyroglobulin ( Figure 5a ). TRK-T1 transgenic thyroids expressed the thyroid dierentiation genes thyroglobulin, thyroid peroxidase and thyroid stimulating hormone receptor at levels similar to RET/PTC3 transgenic mice as measured by RT ± PCR ( Figure 6 ).
TRK-T1 transgenic mice develop thyroid hyperplasia and carcinoma
In order to evaluate the pathological changes associated with TRK-T1 expression, we sacri®ced transgenic mice at various ages between 2 and 24 months old. TRK-T1 transgenic mice, line 5215, were examined Figure 1 Schematic of the construct used to generate the TRK-T1 transgenic mice. BTG-Pro, bovine thyroglobulin promoter (2 kb); b-globin intron (0.7 kb); TPR, translocated promoter region, the 5' TRK-T1 fusion partner (588 bp); NTRK1, the 3' TRK-T1 fusion partner (1158 bp); pA, SV40 polyadenylation signal (1 kb) for pathological changes of the thyroid according to the speci®c criteria outlined in Table 1 . Although thyroids from the 5218 and 5221 TRK-T1 transgenic lines showed similar histological changes, they were not included in Table 2 . Overall, histological examinations of TRK-T1 transgenic thyroids revealed a loss of normal thyroid architecture in 19/35 (54%) of thyroids examined. Interestingly, 16/26 or 62% of the thyroids from transgenic mice 7 months of age or younger were normal, while 100% of thyroids from mice older than 7 months of age showed thyroid abnormalities ( Table 2) . Examination of aected TRK-T1 thyroids revealed increased follicular cellularity together with irregular or colloid-de®cient follicles. This abnormal thyroid architecture was de®ned as hyperplasia and was absent from nontransgenic littermates (Table 1) . In addition, analysis of these hyperplastic TRK-T1 transgenic thyroids also revealed cellular invaginations into the follicle resembling micro-papillary structures often seen in dierentiated human thyroid carcinoma (Figure 4) . Hyperplasia was evident by 3 months of age, but onset was observed as late as 10 months. Furthermore, TRK-T1 transgenic mice developed thyroid carcinoma characterized by the proliferation of follicular epithelial cells containing scant cytoplasm, absent mitotic ®gures and papillae containing ®brovascular stalks ( Figure  5b ), features characteristic of dierentiated carcinomas in humans (Rosai et al., 1990) . Thyroid carcinoma was Figure 2 Western blot analysis of NTRK1 protein expression in TRK-T1 transfected PC C13 cell line. PC C13 cells were cotransfected with either 10 mg TRK-T1 transgenic DNA construct shown in Figure 1 and 1 mg of pSV2-neo or the positive control NTRK1 plasmid pDM-69. Three days after transfection, thyroid cultures were lysed and proteins resolved on a 10% polyacrylamide gel. Following transfer onto nylon and staining using an antibody against NTRK1, expression of the NTRK1 protein was observed in TRK-T1 transfectants (lanes 1 and 2) and in the NTRK1 transfectant positive control (lane 3) but not the negative control (7). Lane (7): untransfected cells; lanes 1, 2: two independent TRK-T1 transfectants; lane 3: pDM-69, NTRK1 transfectant (p140 and p110, fully and partially glycosylated forms) Figure 3 RNAse protection analysis of the three TRK-T1 transgenic mouse lines, 5215, 5218 and 5221. Total RNA was extracted from the thyroids of the three transgenic mouse lines or mouse liver and hybridized to a radiolabeled RNA probe from either the TRK-T1 oncogene (180 bp probe) or b-Actin (330 bp probe) and then RNAse digested. Protected fragments were resolved on a 5% denaturing polyacrylamide gel and visualized by audioradiography found in 6/26 or 23% or mice 7 months of age or younger (Table 2 ). In contrast, 7/9 or 78% of mice older than 7 months of age developed thyroid carcinoma. Solid sheets of cells resembling solid-type carcinoma were rare in tumor bearing TRK-T1 transgenic thyroids. Although human papillary thyroid carcinoma is characterized by distinct nuclear changes and lymphatic spread, we did not observe nuclear abnormalities or tumor metastases in local cervical lymph nodes, peripheral lymph nodes or lungs from TRK-T1 mice. Finally, unlike the 33% of human PTC, which present with lymphocytic in®ltrates (Rosai et al., 1990) , tumors arising in the TRK-T1 mice failed to induce in¯amma-tion. This observation however, likely re¯ects the state of immunological tolerance to unique antigens caused by TRK-T1 gene expression early in development.
Discussion
Two families of translocations involving the protooncogenes, NTRK1 and c-RET, have been found in human papillary thyroid carcinoma (Bongarzone et al., 1989) . The common feature of these families is the fusion of a ubiquitously expressed amino terminal partner to a carboxyl terminal partner containing a growth factor receptor tyrosine kinase domain resulting in the formation of an oncoprotein Sozzi et al., 1992) . These fusion proteins are thought to aberrantly activate mitogenic signaling pathways within the thyrocyte that result in increased growth and cell division (Wynford-Thomas, 1997). Moreover, thyroid hyperplasia may facilitate the accumulation of additional mutations that promote tumor progression and loss of a dierentiated Figure 6 Semi-quantitative RT ± PCR analysis for thyroglobulin, thyroid peroxidase and thyroid stimulating hormone receptor gene expression was performed on nontransgenic, RET/PTC3 and TRK-T1 transgenic mice. Total thyroid RNA from nontransgenic (Nontg), RET/PTC3 and TRK-T1 transgenic mice was isolated, reverse transcribed, and PCR ampli®ed for the following genes: thyroglobulin (Tg), 350 bp; thyroid peroxidase (Tpo), 300 bp; thyroid stimulating hormone receptor (Tshr), 550 bp; RET/PTC3 breakpoint (RET/PTC3), 310 bp; TRK-T1 breakpoint (TRK-T1), 590 bp; and glyceraldehyde-3-phosphate dehydrogenase (G3pdh), 100 bp. PCR was performed after normalizing the amount of template cDNA with reference to G3pdh (see Materials and methods). Control PCR reactions performed without cDNA are indicated as (7). Control PCR reactions performed without reverse transcriptase were negative phenotype. However, analysis of human PTC has revealed variant translocations involving the protooncogene NTRK1, which appears less frequently than translocations involving c-RET (Beimfohr et al., 1999; Bongarzone et al., 1989 Bongarzone et al., , 1996 Bongarzone et al., , 1998a Delvincourt et al., 1996; Fugazzola et al., 1995; Greco et al., 1992; Sozzi et al., 1992; Wajjwalku et al., 1992) . The infrequent occurrence of NTRK1 translocations and their inability to fully transform PC C13 in vitro warranted detailed analysis to measure the strength of their carcinogenic activity in vivo.
The pathology observed in TRK-T1 transgenic mice demonstrates that fusion proteins containing the NTRK1 kinase are oncogenic in the mammalian thyroid. TRK-T1 expression in the thyroid of transgenic mice induced thyroid epithelial cell transformation and hyperplasia that preceded the development of carcinoma indicating that TRK-T1 is sucient to initiate thyroid cancer in vivo. Moreover, the growth of papillae containing ®brovascular stalks in TRK-T1 transgenic mouse thyroids, a histopathological feature observed in human cancer, supports this conclusion. Notably, TRK-T1 carcinomas from all transgenic lines presented with the classic papillary structures, characteristics of human PTC, but infrequently with solidtype papillary carcinoma. In contrast, older RET/ PTC3 and RET/PTC1 transgenic mice frequently developed solid-type carcinomas (Powell et al., 1998; Sagartz et al., 1997) . Although, discrepancies between these models may be explained by subtle dierences in the construct, mouse genetic background or unde®ned environmental factors, they are likely attributable to the function of the individual oncogenes since similar pathology is observed in thyroid tumors from both transgenic mice and humans expressing the RET/PTC fusion proteins (Powell et al., 1998) .
TRK-T1 may be a weaker oncogene in vivo than RET/PTC since 46% of TRK-T1 transgenic mice do not develop any detectable thyroid abnormalities, whereas thyroid carcinomas were observed in all RET/PTC1 (Jhiang et al., 1996) , and hyperplasia or carcinoma in all RET/PTC3 transgenic mice (Powell et al., 1998) . Moreover, a majority of TRK-T1 transgenic mice presented with thyroid carcinoma only after 7 months of age and none of the mice developed poorly dierentiated carcinoma through 24 months of observation. The incomplete penetrance of thyroid hyperplasia along with the lengthy time course for the development of thyroid carcinoma indicates that the TRK-T1 fusion gene may allow thyroid follicular epithelial cells to survive and accumulate other genetic abnormalities that precipitate overt thyroid carcinoma. Consistent with this notion, transplanted RET/PTC3 thyroid carcinomas fail to grow in normal or SCID mice whereas the poorly dierentiated thyroid carcinomas transplanted from RET/PTC p53-/-mice grow progressively (Powell et al., submitted). Thus, TRK-T1 mice crossed with other mice strains, such as those de®cient in tumor suppressor genes or those expressing known oncogenes, may help uncover the pathways controlling thyroid tumor progression from indolent dierentiated to transplantable poorly dierentiated cancers.
The TRK-T1 transgenic mouse strain provides a new animal model to study the various pathological dierences evoked by NTRK1 oncogene expression in thyroid epithelium. We ®nd that the functional comparison between RET/PTC3 and TRK-T1 proteins has revealed dierences in their capability to cause tumors in mice. Importantly, these results may re¯ect dierences in the pathological outcome of papillary cancers observed in human disease. In addition, since these mouse strains reliably recapitulate human disease they provide an ideal system to examine the genetic and compensatory host changes during carcinogenesis. Furthermore, the characterization and study of these mice will aid in improving the diagnosis of human thyroid malignancies and in the testing of new anticancer therapies.
Materials and methods
Development of TRK-T1 transgenic mouse strain
A 5.4 kb DNA transgene was made from the bovine thyroglobulin promoter (2 kb) (Rochefort et al., 1996) , a mammalian b-globin intron (0.7 kb), the human TRK-T1 coding sequence (1.7 kb), and an SV40 polyadenylation signal (1 kb). The transgene was cloned into the pBluescript-II SK + vector (Stratagene, Inc., LaJolla, CA, USA) and plasmid DNA was puri®ed using columns according to manufacturer's protocol (Qiagen, Inc., Santa Clarita, CA, USA). For transgenesis, 2 mg of puri®ed construct DNA was microinjected into zygotes as described (Hogan et al., 1986) . Founder animals were developed by the Kimmel Cancer Institute Transgenic Facility and identi®ed by Southern hybridization using a TRK-T1 speci®c probe (Ausubel et al., 1995) . Founder mice were mated with wild type B6C3F1 and progeny screened for the presence of the transgene by PCR with transgene speci®c primers as described below.
DNA amplification by PCR
PCR was used to determine transgene presence using a modi®cation of existing protocols (Ausubel et al., 1995) . Brie¯y 100 ng of genomic DNA was added to a 50 ml reaction mixture containing 16 PCR buer, 0.2 mM deoxynucleotide triphosphates, 50 pM 3' and 5' oligonucleotides (5' primer sequence of TRK-T1, CACATCATCGA-GAACCCACAA; and 3' primer TRK-T1, GCTCATGCCA-AAATCACCAAT which generate a 550 bp product) and 2.0 U Taq polymerase. The reaction tubes were then placed into a heated lid thermocycler (Hybaid, Inc.) and subjected to 30 cycles of denaturation at 948C for 30 s, annealing at 608C for 30 s, and elongation at 728C for 60 s. PCR products were resolved on a 2% agarose gel and bands visualized with ethidium bromide staining and UV light illumination.
Thyroid cell transformation
The PC C13 thyroid epithelial cell line used in these studies was derived from 18-month-old Fischer rats (Fusco et al., 1987) . PC C13 cells were maintained in Coon's modi®ed F12 *Mouse thyroid pathology followed a bimodal distribution that separated into two populations at 7 months of age. {See Table 1 for the description of pathological criteria used for these data medium (GIBCO-BRL, Paisley, PA, USA) supplemented with 5% calf serum (GIBCO) and six hormones (6H; TSH, insulin, hydrocortisone, somatostain, transferrin and glycylhistidyl-lysine) (Sigma Chemical, Co.), as described elsewhere (Fusco et al., 1987) . 5610 5 cells were plated 48 h before transfection in 60 mm tissue culture dishes. Three hours prior to transfection, the medium was changed to Dulbecco's modi®ed Eagle's medium (DMEM) (GIBCO) containing 5% calf serum and 6H. Calcium phosphate precipitates of DNA (10 mg of TRK-T1 or NTRK1 (pDM-69) plasmid and 1 mg of pSV2-neo) were prepared as reported elsewhere (Fusco et al., 1987) and were incubated with the cells for 1 h. DNA precipitates were removed and cells were incubated in 15% glycerol for 2 min. Cells were washed with DMEM and incubated for 48 h in Coon's modi®ed F12 medium supplemented with 5% calf serum and 6H. Transfectants were selected in 400 mg/ml Geneticin (G418, GibcoBRL). Two independent populations were obtained for the TRK-T1 transfection and one for the NTRK1 transfection. Protein extractions and Western blot analysis (20 mg of total protein) were performed according to standard procedures. Immune complexes were detected with the enhanced chemiluminescence kit (Amersham Corp). The anti-TRK rabbit polyclonal antibody (c-14) was purchased from SantaCruz Biotechnology Inc. The NTRK1 expressing plasmid, pDM-69, used as a positive control was a gift from Dr M Barbacid, Bristol Myers Squibb.
RNAse protection analysis (RPA)
Thyroid tissue was removed from transgenic mice and homogenized in 0.5 ml of cell lysis buer (4 M Guanidinium thiocyanate, 25 mM Sodium citrate, 0.5% Sodium Nlauroylsarcosine, 0.1 M 2-mercaptoethanol) using a mechanical homogenizer (Biospec Products, Racine, WI, USA). Protein was removed using phenol: chloroform extraction (1 : 1), while nucleic acid was recovered following ethanol precipitation. DNA was removed using RNAse free DNAse (Ambion). TRK-T1 riboprobe was synthesized from a 180 bp cloned fragment (1054 ± 1236) of the TRK-T1 gene, while the control actin riboprobe was synthesized from a 330 bp vector (Ambion). Riboprobes and thyroid RNA were precipitated together, resuspended in 20 ml of hybridization buer (80% deionized formamide, 100 mM sodium citrate, pH 6.4, 300 mM sodium acetate, pH 6.4, 1 mM EDTA) and incubated overnight at 428C. RNA hybrids were digested with 40 mg/ml RNAse A and 2 mg/ml RNAse T1 for 30 min at 378C. RNA was precipitated, resuspended in gel loading buer (95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 0.5 M EDTA, 0.025% SDS), denatured for 3 min at 948C and resolved on a 5% denaturing polyacrylamide gel for 1 h at 250 volts. Gels were dried and exposed to X-ray ®lm.
Immunocytochemistry and pathological analysis TRK-T1 transgenic mice between 2 and 24 months of age were sacri®ced and thyroid, lung, cervical and peripheral lymph nodes (popliteal and para-aortic) were removed for pathological examination. Immunohistochemical analysis of protein expression in mouse tissues was performed using established laboratory protocols (Powell et al., 1998) . Brie¯y, tissues were ®xed in 10% formalin for 24 h and desiccated. Following ®xation, tissue samples were embedded in liquid paran and cooled. Paran-embedded tissue was sliced into 6 mM sections and placed on silanized slides (Fisher Scienti®c). After deparanization in xylenes, the sections were hydrated through decreasing concentrations of alcohol and microwaved for 15 min in 100 mM citrate buer (pH 6.0). Sections were blocked with 10% normal goat serum for 15 min and incubated with a rabbit polyclonal antibody against TRK A (1 : 500, TRK-763, Santa Cruz Biotechnology) or mouse monoclonal antibody against thyroglobulin (1 : 500, Harlan Sera-Lab, Loughborough, UK) overnight at room temperature. The following day, sections were washed twice for 5 min each with phosphate buered saline (PBS) and once for 5 min with PBS/1% bovine serum. Sections were incubated with biotinylated secondary antibody for 1 h at room temperature, washed and incubated with substrate according to the DAB Vectastain kit (Vector Labs, Inc.), counterstained using hematoxylin, dehydrated and mounted. Thyroid sections were examined by a board-certi®ed surgical pathologist (M Cunnane) and pathological criteria assessed.
Semi-quantitative RT ± PCR analysis
Five mg total RNA was isolated as described above from TRK-T1 transgenic and nontransgenic mouse thyroid, reverse transcribed (Superscript II, GibcoBRL) and cDNA ampli®ed in a semi quantitative PCR after cDNA had been normalized using primers speci®c to glyceraldehyde-3-phosphate dehydrogenase (G3pdh). The murine G3pdh speci®c PCR primers were 5' primer CCTTCATTGACCTCAACTAC and 3' primer ATGACAAGCTTCCCATTCTC. Semi-quantitative PCR was then performed utilizing murine primers speci®c for thyroglobulin (5' primer CCTGGTCTTGTGGGTCTCTA and 3' primer GAGGAAGGTAGAGAGCATCG), thyroid peroxidase (5' primer ATGAGAACACTTGGAGCTAT and 3' primer GACTTGTATTGATGTTTCCA), thyroid stimulating hormone receptor (5' primer GCAAAGAGTGTGC-GTCTCCA and 3' primer GCATCCAGCTTTGTTCCATT) and human primers speci®c for the RET/PTC3 (5' primer TGGAGAAGAGGAGCTGTATC and 3' primer CTTTCA-GCATCTTCACGG) and TRK-T1 (5' primer GCGGTGTT-GCAGCAAGTCCT and 3' primer CGATGATGTGGCCT-TGGAGC) breakpoints as described above. The PCR product sizes generated were: G3pdh, 100 bp; thyroglobulin, 350 bp; thyroid peroxidase 300 bp; thyroid stimulating hormone receptor, 550 bp; TRK-T1 breakpoint, 590; and RET/PTC3 breakpoint, 310 bp. Control PCR reactions performed without cDNA did not produce any products. In addition, all RNA samples were sham reverse transcribed and PCR ampli®ed to ensure that ampli®cation products were derived from cDNA and not contaminating genomic DNA (-RT control).
